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Summary
Introduction: Treatment of infection after total hip replacement (THR) is complex and costly.
Debridement with component retention is an attractive solution. Success rates in the literature
vary widely (18—90%) according to patient selection criteria. The present prospective study
assessed the selection criteria used in our department.
Methods: A prospective study included all patients (n = 210) surgically managed for infection
following THR between November 2002 and December 2008. Patients underwent debridement in
case of acute infection: i.e., early postoperative infection within 1month of THR, or secondary
hematogenic infection with less than 2weeks’ evolution. Beyond this deadline or in case of
implant loosening, implant replacement was performed. The debridement series thus comprised
12 patients (mean age, 69± 11.3 years; mean evolution from contamination was 4.8± 3.5 days).
Bacteriologically adapted antibiotherapy was administered for 6weeks intravenously followed
by 6weeks per os. Mean follow-up was 40± 23months. No patient was lost to follow-up. The suc-
cess criterion was apparent eradication of infection at a minimum 2 years, deﬁned by absence
of clinical, biological or radiological signs of infection and of death attributable to infection or
treatment. Where infection was suspected, hip aspiration or peroperative sampling determined
recurrence (identical bacterium) or reinfection (different bacterium).
Results: There were nine cures (75%) and three failures. Mean Postel Merle d’Aubigné Score, at
end of follow-up, was 17± 2. The three failures involved the same bacteria (two streptococci
[one group B, one groupG] and one Enterococcus faecalis) as implicated in the primary infection.
Discussion: The present results are comparable to those in the literature but poorer than for
implant exchange. The technique remains, however, an interesting alternative, allowing less
complex surgery and lower cost.
∗ Corresponding author. Tel.: +33 6 28 35 04 78.
E-mail address: klouche shahnaz@yahoo.fr (S. Klouche).
877-0568/$ – see front matter © 2011 Elsevier Masson SAS. All rights reserved.
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Conclusion: Patient selection criteria need reﬁning so as to increase success rates with this
technique.
Level of evidence: Level IV; prospective non-randomized non-comparative study.
© 2011 Elsevier Masson SAS. All rights reserved.
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The implant was dislocated so as to treat all inter-Introduction
Treating infection in total hip replacement (THR) is complex
and costly [1,2]. Debridement with components retention is
an option which, under certain conditions, may be inter-
esting. The surgical operation is lighter from the patient’s
point of view, allows earlier recovery of joint function, and
is less costly than implant replacement. Success rates in the
literature vary widely, from 18 to 90% [3—16], and depend
on patient selection criteria. Rigorous selection, large-
scale debridement and precise bacteriological adaptation
of antibiotherapy are the keys to success [8]. Several risk
factors for failure have been identiﬁed [8,12]: essentially,
more than 2weeks’ evolution of infection, comorbidity, and
ﬁstula. The present prospective study assessed the selection
criteria employed in our department.
Patients and methods
Inclusion and exclusion criteria
A prospective observational study was run from Novem-
ber 2002 to December 2008. On our departmental decision
tree, debridement was indicated in case of acute infection:
i.e., on Tsukayama’s classiﬁcation [14], early postoperative
infection less than 1month post-implantation or secondary
hematogenic infection of less than 2weeks’ evolution. Sec-
ondary infection was diagnosed for a combination of remote
infection, positive blood-culture and detection around the
implant of a bacterium other than those commonly asso-
ciated with peroperative contamination [17]. Exclusion
criteria included radiologic signs of bone infection (e.g.,
periosteal apposition or osteolysis around the implant) or
of implant loosening. In case of more than 2weeks’ evo-
lution or of loosening, implant replacement was indicated.
Surgery was followed by adapted antibiotherapy maintained
for a maximum of 3months. Only cases of curative debride-
ment (i.e., without prescription of lifetime suppressive
antibiotics) were included in the study. In case of failure,
debridement was not repeated, and some other treatment
option was undertaken. Patients gave written informed con-
sent and the study received ethics committee approval.
Success criterion
The criterion of success was apparent resolution of the ini-
tial infection at a minimum 2 years’ follow-up, deﬁned by
absence of clinical, biological and radiological implant infec-
tion signs or of death directly implicating the infection or
treatment.
f
f
watients
etween November 2002 and December 2008, 210 THR
mplant infections were managed surgically in the
epartment. One-stage replacement was performed in
06 patients, 2-stage replacement in 76 patients and resec-
ion or coaptation in 16. Twelve patients were managed by
urative debridement with retention of components (with
r without femoral head or acetabular insert replacement):
ve men, seven women; mean age, 69± 11.3 years. On
he American Society of Anaesthesiologists classiﬁcation,
patient was ASA-1, 10 were ASA-2 and 1 was ASA-3. The
nitial pathology underlying THR was primitive osteoarthritis
f the hip in eight patients, secondary osteoarthritis in
hree (one post-tuberculosis [with negative bacteriology at
mplantation], secondary to radiation therapy in one and to
egg-Calve-Perthes disease in one) and osteonecrosis of the
ip in one. Mean evolution between estimated ﬁrst signs
nd debridement was 4.8± 3.5 days (range, 1 to 11 days).
ontamination was early postoperative in two patients who
ad undergone THR in the department, and probably sec-
ndary in 10. The entry point was identiﬁed in eight patients
Table 1). Clinically, onset was sudden in all cases, with
ean 39± 0,5 ◦C fever, chill, hip pain and varying degrees
f functional impairment. Mean preoperative Postel Merle
’Aubigné Score was 8.9± 4.2. Soft tissue was normal in
even patients, inﬂammatory or abscessed in four, and one
atient developed a productive ﬁstula 4 days before surgery.
iologically, mean leukocyte count was 10,763/mm3 (range,
,830 to 27,280), erythrocyte sedimentation rate 74 (range,
3 to 120) and C-reactive protein 186.2mg/l (range, 72
o 335). Preoperative hip aspiration was performed in
1 patients. In one patient, a simple Cathlon catheter
ample was taken from the scar, isolating groupG strepto-
occus. In 10 aspirates, the culprit bacterium was identiﬁed
one being negative due to preoperative antibiotherapy),
ith a mean joint-liquid cell-count of 108,969/mm3 (range,
400 to 580,000) including a mean 93% (range, 77 to 99%)
olynuclear neutrophils. Seven of the 12 patients had
emented implants. Mean hospital stay was 22 days (range,
4 to 35 days). Mean follow-up was 3.5 years, with no loss to
ollow-up.
urgery
pen debridement used the previous approach. Syn-
vectomy was large (anterior, posterior, superior and
nferior), involving all abscessed and necrotic joint and
eriprosthetic regions and any periarticular ossiﬁcations.aces, and tested peroperatively for loosening. Where
easible, the femoral head and/or acetabular insert
as replaced: in four cases for the femoral head
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Table 1 Entry point and isolates.
Age(yrs) Sex Number of
previous
operations on site
Infection
evolution
(days)
Type of
contamination
Entry point Culprit bacterium
Patient 1 58 M 1 10 Secondary Staphylococcus aureus MS
Patient 2 74 M 1 1 Secondary Digestive Streptococcus group B
Patient 3 83 F 1 7 Early postop. Streptococcus
groupG + Staphylococcus
aureus MS
Patient 4a 81 F 1 2 Secondary Cutaneous Streptococcus group B
Patient 5 74 F 3 3 Secondary ENT Streptococcus pneumoniae
Patient 6 85 F 3 9 Secondary Citrobacter freundii
Patient 7 63 F 2 4 Secondary Genital Enterococcus faecalis
Patient 8a 68 M 2 11 Secondary Urinary Enterococcus faecalis
Patient 9 53 M 2 2 Secondary Dental Streptococcus mitis
Patient 10a 78 F 2 3 Secondary Cutaneous Streptococcus groupG
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a Failures.
lone, with associated polyethylene insert replacement in
wo.
ntibiotherapy
reoperative antibiotherapy was systematically initiated
ollowing the preoperative hip aspiration. It consisted of
.v. biantibiotherapy at effective dose, initially probabilis-
ic then quickly adapted to the aspiration ﬁndings. No local
ntibiotherapy was administered. I.v. antibiotherapy was
aintained for 6weeks, followed by 6weeks’ oral admin-
stration. Tolerance was satisfactory.
acteriology
t least three staggered deep peroperative samples were
aken. Isolates are shown in Table 1.
esults
ach patient underwent a single debridement. The 2-year
uccess rate was 75%. Mean Postel Merle d’Aubigné score at
nd of follow-up was 17± 2.
There were three failures due to recurrence of infection
mplicating the primary bacterium (Table 2).
The ﬁrst failure concerned an 81 year-old woman with
ype-2 diabetes, ASA 3. The cemented THR had been
mplanted 2months previously, for primitive osteoarthritis
f the hip. Group B streptococcus was implicated. Contami-
ation was considered to be secondary, as the entry point,
onﬁrmed by a local bacteriological sample, was a bedsore
n the heel contracted during her previous admission. The
nterval between ﬁrst signs of infection and debridement
as 2 days. Antibiotherapy was maintained for 6weeks, by
.v. route only, as the patient failed to take her oral treat-
ent. Relapse occurred 2weeks after end of antibiotherapy,
ith total functional impotence without fever or chill, and
as conﬁrmed by hip aspiration. Given the patient’s age
a
r
T
s
aEarly postop. Streptococcus groupG
Secondary Digestive Streptococcus group B
nd terrain, minimal debridement was undertaken, with
weeks’ i.v. antibiotherapy followed by a lifetime suppres-
ive regime (cefalexin 1 g× 3 daily). With this treatment,
nfection appeared stable at 5 years’ follow-up.
The second failure concerned a young man operated on
or bladder stones. Infection was secondary to the urinary
ntry point. Following a documented urinary infection impli-
ating Enterococcus faecalis, the patient showed hip pain,
ever, chill and functional impairment. The interval between
he ﬁrst signs of infection and debridement with femoral
ead replacement was 11 days. Recurrence was observed
months after the end of antibiotherapy, with hip pain but
o fever. Hip aspiration conﬁrmed recurrence implicating
he initial bacterium. One-stage replacement was associ-
ted to adapted antibiotherapy (6weeks i.v. followed by
weeks per os). At 4 years’ follow-up, the infection had
esolved.
The third failure concerned a 78-year-old woman, with-
ut comorbidity, who had undergone previously implant
eplacement by trochanterotomy for recurrent dislocation.
he infection was considered probably secondary, in view of
skin wound sustained 4 days before the onset of clinical
igns and of the type of bacterium (groupG streptococ-
us) isolated. Relapse occurred a few days after the end
f antibiotherapy, as conﬁrmed on hip aspiration. One-stage
eplacement was associated to adapted antibiotherapy. At
years’ follow-up, the infection had resolved.
iscussion
here are, to the best of our knowledge, no reports of
rospective studies of debridement in infected THR. The
resent 75% success rate at a minimum 2-years’ follow-up
fter a single surgical procedure is comparable to the most
ecent reports (Table 3). At a minimum 2-years’ follow-up,
sukayama et al. [16] had a 68% success rate after a single
urgical procedure, and Marculescu et al. [12] 60% after iter-
tive debridement in hip and knee implants taken together.
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Table 2 Analysis of the three cases of recurrence implicating same bacterium.
Patient 4 Patient 8 Patient 10
Age 81 68 78
Sex F H F
Morbidity Type-2 diabetes Bladder stones
ASA score 3 2 2
Age of THR (months) 2 55 2
Type of THR Cemented Cemented Cemented
Number of previous operations on site 1 2 2
Soft-tissue status Inﬂammatory Inﬂammatory Inﬂammatory
Estimated infection evolution (days) 2 11 3
Type of contamination Secondary Secondary Secondary
Entry point Cutaneous Urinary Cutaneous (probable)
Isolate Streptococcus group B Enterococcus faecalis Streptococcus groupG
Femoral head and/or insert replacement No Femoral head No
I.v. antibiotics (weeks) 6 6 6
Per os antibiotics (weeks) 0 6 6
Time to relapse after cessation of
antibiotherapy (months)
< 1 3 < 1
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e
m
r
h
b
a
d
a
m
p
h
c
t
b
p
tRevision Debridement + life
Follow-up (years) 5
Estes et al. [14] reported a 90% success rate at a mini-
mum 2-years’ follow-up after a 2-stage procedure. All these
results, however, are poorer than found with 1- or 2-stage
THR implant replacement [16,18].
Several risk factors for failure were reported. The most
widely accepted is the interval to debridement after onset of
signs, with elevated risk of failure after eight days according
to Marculescu et al. [12], four according to Meehan et al.
[10] and two according to Brandt et al. [4]. The other failure
factors reported in the literature are: comorbidity, ﬁstula
and implant loosening [6,9,12]. Resection quality is a success
factor: resection should be large and meticulous.
In our department during the study period, only 12
out of 210 patients met the criteria for debridement with
retention of components: i.e., postoperative infection fol-
lowing THR performed less than 1month previously or
presumed acute infection with less than 2weeks’ evolu-
tion between onset of clinical signs and surgery, without
implant loosening and with known bacterium. These condi-
tions enhance the chances of success and appear necessary
for debridement to be indicated but not sufﬁcient to
r
d
t
Table 3 Examples of studies of debridement in infected total hip
Author Infection site Date Number of patients
Tsukayama et al. [16] Hip 1996 41
Tattevin et al. [7] Hip Knee 1999 34
Lhotellier [8] Hip 2002 52
Meehan et al. [10] Hip Knee 2003 19
Marculescu et al. [12] Hip Knee 2006 99
Aboltins et al. [13] Hip Knee 2007 20
Estes et al. [14] Hip Knee 2010 20antibiotics 1-stage replacement 1-stage replacement
4 2
nsure the success rates obtained with implant replace-
ent.
The present series lacked power to perform multivariate
isk-factor analysis; even so, we put forward the following
ypotheses. In the ﬁrst case of failure, the causes may have
een advanced age in an ASA-3 patient, and the duration of
ntibiotherapy, which was not extended by a per os course
ue to non-compliance. In the second case, the THR was
lmost 5 years old; the infection was considered acute, but
ay have been an acute episode in a chronic infection in a
atient with a long history of bladder stones, for which he
ad been operated on: the infection implicated Enterococ-
us faecalis, also isolated in urine cytobacteriology. In the
hird case, the patient had previously undergone revision
y trochanterotomy, requiring repair by cerclage only the
rojecting part of which could be removed on debridement:
he remaining material may have been responsible for the
elapse.
Two of these failures were thus probably due to previously
escribed risk factors: comorbidity and insufﬁcient resec-
ion. In the third case, evolution had probably been longer
replacement.
Mean F.U.(yrs) Number of procedures Success rate (%)
3.8 1 68
1.6 1 38.2
4.7 1 79
3.9 1 to 3 89.5
2 1 to 4 60
2.7 1 to 4 90
2.4 2-stage 90
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[38
han thought: it is very difﬁcult to be sure that an infection
s acute [17], and estimated intervals between clinical onset
nd revision probably underestimate evolution as there is an
ccult interval between implant contamination and clinical
xpression which may amount to several days. Secondary
nfection is thus a very different matter from acute per-
r perioperative infection, where the date of implantation
nd thus the earliest possible date of contamination are
nown with certainty. In the present series, all three failures
nvolved infection deemed to be secondary.
Debridement is certainly a cheaper treatment option
han implant replacement, when it meets with success. In
ur own departmental cost analysis [1], the duration of the
tay in the surgery department and in postoperative care
nd rehabilitation accounted for the extra cost associated
ith management of infected THR as compared to infection-
ree revision and primary THR. In the case of debridement,
he mean stay in surgery was shorter and home care was
ore often possible for i.v. antibiotherapy monitoring with
hysiotherapy sessions at home. Moreover, the cost does not
nclude the mean cost of the implant. It should, however, be
orne in mind that failure of a component-retention proce-
ure entails the extra cost of subsequent replacement.
Certain authors reported increased success rates with
ncreased number of procedures [10,12,13], but at the cost
f extending hospital stay and multiplying the number of
urgical operations; we feel that this is of little beneﬁt in
erms of quality of life for the patient or of economy for the
ommunity, compared to primary 1-stage replacement.
The main limit of the present study was the small number
f patients, preventing statistical analysis of risk factors for
ailure.
onclusion
ebridement is certainly an interesting treatment option,
ut the success rate is clearly lower than for implant
eplacement. In case of relapse, all of the beneﬁt for
oth patient and community is wiped out. Comorbidity
hould always be included in the decision tree and, in
ase of doubt as to the real time of evolution in an infec-
ion considered to be secondary, we recommend implant
eplacement.
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